Login to Your Account



Late-stage evolution for Intra-Cellular; firm raises $107M, jumps to Nasdaq

By Jennifer Boggs
Managing Editor

Friday, January 31, 2014
With an eye toward launching a Phase III program in schizophrenia later this year, Intra-Cellular Therapies Inc. priced a $107.5 million public offering after market close Thursday, selling about 6.1 million shares priced at $17.50 apiece.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription